My guess is that 700 mg topline results were not g
Post# of 153903
(Total Views: 752)
Posted On: 01/05/2022 2:58:22 PM
Re: Borel Fields #113838
My guess is that 700 mg topline results were not good, and they are looking at CCR5 haplotype (as mentioned in PR) and other biomarker data to be able to explain why not before they release that information. But that is the pessimist in me who wonders why they wouldn't release the 700 mg PE results if they have the topline results (they should if they have them for placebo) and they were good.
The optimist can hope there are other reasons why 700 mg results weren't released yet (or any numbers really, even for 350 mg dose), besides that they have them and they are not good enough: busy statisticians / staff shortages due to holidays and Omicron could be one reason. It's possible they don't have the topline 700 mg results yet. Perhaps they are waiting on lab results, like the CCR5 haplotype data they mentioned, or as you suggest perhaps receptor occupancy data for comparison of 350 mg vs. 700 mg dose groups. Could be lots of things.
Sometimes it's hard to keep the faith as we continue the long drip down and have been disappointed with promising but not good enough results thus far in our other trials, combined with muddied communications. Mostly we are just in a really tough market for biotech, and CYDY has very many critics and not much credibility, sadly. But leronlimab has so much promise, it's certainly a good bet IMO especially at this price and I haven't sold anything since my last purchase 18+ months ago. The cancer indication seems most promising of all. HIV should be a lock, with NASH and Covid bonus upside indications.
The optimist can hope there are other reasons why 700 mg results weren't released yet (or any numbers really, even for 350 mg dose), besides that they have them and they are not good enough: busy statisticians / staff shortages due to holidays and Omicron could be one reason. It's possible they don't have the topline 700 mg results yet. Perhaps they are waiting on lab results, like the CCR5 haplotype data they mentioned, or as you suggest perhaps receptor occupancy data for comparison of 350 mg vs. 700 mg dose groups. Could be lots of things.
Sometimes it's hard to keep the faith as we continue the long drip down and have been disappointed with promising but not good enough results thus far in our other trials, combined with muddied communications. Mostly we are just in a really tough market for biotech, and CYDY has very many critics and not much credibility, sadly. But leronlimab has so much promise, it's certainly a good bet IMO especially at this price and I haven't sold anything since my last purchase 18+ months ago. The cancer indication seems most promising of all. HIV should be a lock, with NASH and Covid bonus upside indications.
(7)
(2)